Anika Therapeutics (ANIK) Total Liabilities (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Total Liabilities data on file, last reported at $45.5 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $45.5 million, up 7.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.5 million (up 7.77% YoY), and the FY2025 annual result was $46.8 million, down 3.99% from the prior year.
• Total Liabilities eased to $45.5 million in Q1 2026 per ANIK's latest filing, from $46.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $68.0 million in Q2 2022 and troughed at $40.0 million in Q2 2025.
• A 5-year average of $53.4 million and a median of $54.9 million in 2023 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities tumbled 34.05% in 2022, then grew 8.92% in 2023.
• A 5-year view of Total Liabilities shows it stood at $63.6 million in 2022, then retreated by 8.18% to $58.4 million in 2023, then declined by 16.48% to $48.8 million in 2024, then slipped by 3.99% to $46.8 million in 2025, then dropped by 2.82% to $45.5 million in 2026.
• Business Quant data shows ANIK's Total Liabilities at $45.5 million in Q1 2026, $46.8 million in Q4 2025, and $42.6 million in Q3 2025.